

11-19-2014

## Predicting Invasiveness in Early Stage Lung Cancer

Julie Linek, MD

*Fellow, Division of Pulmonary, Critical Care, and Sleep Medicine Icahn School of Medicine at Mount Sinai  
New York, NY*

Follow this and additional works at: <https://jdc.jefferson.edu/pulmcritcaregrandrounds>

 Part of the [Medicine and Health Sciences Commons](#)

[Let us know how access to this document benefits you](#)

---

### Recommended Citation

Linek, MD, Julie, "Predicting Invasiveness in Early Stage Lung Cancer" (2014). *Division of Pulmonary and Critical Care Medicine Presentations and Grand Rounds*. Presentation 115.  
<https://jdc.jefferson.edu/pulmcritcaregrandrounds/115>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Division of Pulmonary and Critical Care Medicine Presentations and Grand Rounds by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [JeffersonDigitalCommons@jefferson.edu](mailto:JeffersonDigitalCommons@jefferson.edu).

# Predicting Invasiveness in Early Stage Lung Cancer

---

**Julie (Linek) Barta, MD**

November 19, 2014

Division of Pulmonary, Critical Care, and Sleep Medicine  
Icahn School of Medicine at Mount Sinai, New York

# Outline

- Clinical case
- Invasion and metastasis
- Biomarkers of invasion
  - Biomarker validation
  - High-throughput approaches to biomarker discovery
- Clinical approaches
  - Role of FNA in the diagnosis of lung cancer
- Future directions
  - Important tumor biology and clinical questions


# Clinical case

- A 73 year-old man presents with a RUL nodule since 2010, when he first presented with a cough.
- PMHx: COPD, peripheral vascular disease, obesity (BMI=30.4)
- Smoking history: Former smoker, 1 pack per day for 40 years, quit 13 years ago
- PFTs: Mild obstruction (FEV1= 1.9 L, 66% predicted)

# CT chest


**September 2010**

8mm mixed partly ground glass/  
partly solid nodule



**July 2014**

Increase in solid component to  
7mm, with peripheral ground glass  
component now measuring 1.3cm



# FNA


July 2014

Non-small cell  
carcinoma, favor  
adenocarcinoma

CK7 positive

CK20 negative

TTF-1 positive






# PET-CT


July 2014

Minimally FDG-  
avid (SUVmax 1.5)  
1.8cm RUL opacity







# VATS RUL wedge resection and mediastinal lymph node dissection






## Lepidic predominant adenocarcinoma (LPA)




# Lung adenocarcinoma: Invasion and metastasis

# Lung cancer is a heterogeneous disease


## Bronchogenic Carcinoma



## NSCLC




## Adenocarcinoma



\*EGFR  
KRAS  
EML4/ALK

# Tumor invasion and metastasis



## Initial step for metastasis:

- Loss of adhesion, mobility, basement membrane degradation


## Subsequent steps:

- Intravasation into circulation, extravasation, and angiogenesis at target site



# Adenocarcinoma subtype is defined by degree of tumor invasion



- Lung adenocarcinoma histologic subtypes are associated with tumor invasion and have characteristic radiologic correlates.
- The degree of tumor invasion on histologic examination predicts clinical outcomes.



**Adenocarcinoma  
in situ**



**Invasive  
adenocarcinoma**

# Extent of invasion is independently associated with survival in stage I, II, IIIA adenocarcinoma (n=183)





Category	Median survival
BAC	Not reached
Microinvasive (≤ 5mm)	Not reached
Mixed Subtype	2421 days
Pure Invasive	1980 days

# Lung adenocarcinoma progression is associated with differentially expressed genes



# Mediators of lung adenocarcinoma invasion in TGF $\beta$ RII–deficient tumors




Migration  
MEMBRANE DEGRADATION  
Fibroblast Proliferation  
Fibronectin Deposition  
Macrophage accumulation/  
activation  
Angiogenesis





# LOX family genes and CCL5 are differentially expressed in invasive lung adenocarcinoma

Affymetrix Probe Set ID	GO Function/Gene Name	Gene Symbol	Fold Change*
<b>Adhesion</b>			
201130_s_at	Cadherin 1, type 1, E-cadherin (epithelial)	CDH1	0.23
205328_at	Claudin 10	CLDN10	2.94
204750_s_at	Desmocollin 2	DSC2	0.42
204751_x_at	Desmocollin 2	DSC2	0.42
202267_at	Laminin, $\gamma$ 2	LAMC2	0.38
203726_s_at	Laminin, $\alpha$ 3	LAMA3	0.29
208083_s_at	Integrin, $\beta$ 6	ITGB6	0.13
208084_at	Integrin, $\beta$ 6	ITGB6	0.24
226535_at	Integrin, $\beta$ 6	ITGB6	0.42
215446_s_at	Lysyl oxidase	LOX	4.00
202998_s_at	Lysyl oxidase-like 2	LOXL2	2.70
214154_s_at	Plakophilin 2	PKP2	0.17
207717_s_at	Plakophilin 2	PKP2	0.42
<b>Cell-Cell Signaling</b>			
205290_s_at	Bone morphogenetic protein 2	BMP2	0.18
205289_at	Bone morphogenetic protein 2	BMP2	0.22
1405_i_at	Chemokine (C-C motif) ligand 5	CCL5	3.70
1555759_a_at	Chemokine (C-C motif) ligand 5	CCL5	2.94


# CCL5/RANTES and LOX and LOXL2 are important mediators of lung adenocarcinoma invasion in TGF $\beta$ RII-deficient tumors



# CCR5/RANTES expression in lung adenocarcinoma is associated with **invasion** and clinical outcome




# CCR5/RANTES expression in lung adenocarcinoma is associated with invasion and **clinical outcome**





# Lysyl oxidase (LOX) acts on the ECM to facilitate fibrosis, tumor cell invasion, and metastasis



# Lysyl Oxidase: A Lung Adenocarcinoma Biomarker of Invasion and Survival


May-Lin Wilgus, MD<sup>1</sup>; Alain C. Borczuk, MD<sup>2</sup>; Mark Stoopler, MD<sup>3</sup>; Mark Ginsburg, MD<sup>4</sup>; Lyall Gorenstein, MD<sup>4</sup>; Joshua R. Sonett, MD<sup>4</sup>; and Charles A. Powell, MD<sup>1</sup>

**Table 2.** Tumor LOX Expression Is Associated With Invasive Subclass

Tumor	Low LOX Staining, No. of Cases (% Each Subclass)	High LOX Staining, No. of Cases (% Each Subclass)
Pure BAC	10 (100%)	0 (0%)
Microinvasive	19 (86%)	3 (14%)
Mixed-type	65 (82%)	14 (18%)
Invasive	34 (62%)	21 (38%)

LOX indicates lysyl oxidase; BAC, bronchioloalveolar cancer.

**Survival - All Patients**



**Figure 2.** Survival for all patients is shown. High lysyl oxidase (LOX) expression is associated with increased 5-year mortality (log-rank  $P < .001$ ).

# The LOX family of proteins has been implicated as both tumor suppressors and metastasis promoters

- Lysyl oxidase (LOX) and LOXL2 are important for lung and breast tumor invasion. Expression distinguishes pre-invasive from invasive histology and is associated with poor survival in lung adenocarcinoma.




Table 2 | **The LOX family in cancer**

Cancer	Member	Role
Colorectal	LOX	Increased expression associated with increased invasion, metastatic potential and SRC activation
	LOXL2	Co-expression with RAMP3 and TIMP1 in tumour versus normal tissue Increased expression in tumour-associated stroma versus normal stroma
Bladder	LOXL1 and LOXL4	Epigenetic silencing of <i>LOXL1</i> and <i>LOXL4</i> detected
Pancreatic	LOXL2	Silencing renders cells sensitive to chemotherapy
		Increased expression in adenocarcinoma-associated stroma versus normal stroma
Breast	LOX	Increased expression associated with increased metastasis and decreased survival
	LOXL2	Aberrant and decreased expression significantly correlated with distant metastatic incidence and poor survival
		Co-expression with RAMP3 in tumour versus normal tissue
		Increased expression in tumour-associated stroma versus normal stroma
HNSCC	LOX	Increased expression associated with decreased patient disease-free and overall survival
Laryngeal	LOXL2	Increased expression in stroma and tumour cells is associated with decreased survival
Lung	LOXL2	Increased expression is associated with decreased survival
		Decreased mRNA in tumour versus non-tumour tissue is associated with disease progression
Gastric	LOXL2	Co-expression with RAMP3 in tumour versus normal tissue
Barker, <i>Nature Reviews Cancer</i> , 2012		Increased expression in tumours promotes progression and can be abrogated by immunological targeting



# Early Stage Lung Cancer: Biomarker discovery, validation, and new applications

# Hypothesis

- Gap: There is a need for validated biomarkers in pre-resection specimens that predict tumor invasion and metastasis.
- **Cellular expression of LOX and LOXL2 in pre-resection cytologic specimens predicts lung adenocarcinoma invasiveness.**
- Objective: To examine the association of LOX and LOXL2 expression in fine needle aspirate (FNA) cytology specimens with extent of invasion in paired, surgically resected lung adenocarcinoma specimens.

# Methodology

- LOX and LOXL2 gene expression was performed by **quantitative polymerase chain reaction (qPCR)** of RNA extracted from surgically resected formalin fixed and paraffin embedded (FFPE) tumors and using Taqman probes.
- **Immunohistochemistry (IHC) /Immunocytochemistry (ICC)** for LOX and LOXL2 expression was performed on FFPE cytologic cell blocks from FNAs and paired, surgically resected FFPE tumors.
- Immunostaining in tumor cell cytoplasm was scored as negative (0) or positive on a scale of 1 (faint) to 3 (strong). In positive cases, an assessment of percent staining within tumors was performed.


1° antibody	Tissue	Cytology cell block	Source
Anti-LOX	1:3000	1:3000	Abcam
Anti-LOXL2	1:1000	1:1000	Santa Cruz Biotechnology

# Patient and tumor demographics

Demographics	Tumors (31)
Age, mean $\pm$ SD, y	70 $\pm$ 9
Male, n	12 (38%)
Tumor size, mean $\pm$ SD, cm	1.7 $\pm$ 1.1
<b>Pathologic stage, n</b>	
IA	28 (91%)
IB	2 (6%)
2A	1 (3%)
<b>Adenocarcinoma subtype, n</b>	
Adenocarcinoma in situ (AIS)	3 (10%)
Minimally invasive adenocarcinoma (MIA)	9 (29%)
Lepidic predominant adenocarcinoma (LPA)	4 (13%)
Invasive, acinar predominant	9 (29%)
Invasive, papillary predominant	4 (13%)
Invasive, solid predominant	2 (6%)
<b>Molecular markers, n</b>	
EGFR	4 (13%)
KRAS	4 (13%)
ALK gene rearrangement	1 (3%)





# LOX and LOXL2 expression is higher in resected invasive lung adenocarcinoma compared with noninvasive tumors





# LOX expression in lung adenocarcinoma

**Surgically  
resected  
tumor**



**Cytologic  
cell block  
from FNA**




# The frequency of LOXL2 expression is reduced in pre-invasive resected adenocarcinoma

Cytoplasmic staining positive*	AIS	MIA	LPA	Invasive non-solid	Invasive solid
<b>LOX</b>					
Surgical specimens, n= 19/31	1/3 (33%)	7/9 (78%)	2/4 (50%)	7/10 (70%)	2/5 (40%)
Cytologic specimens, n= 17/18	No specimens	6/6 (100%)	0/1 (0%)	6/6 (100%)	5/5 (100%)
<b>LOXL2</b>					
Surgical specimens, n= 25/31	2/3 (67%)	7/9 (78%)	4/4 (100%)	10/10 (100%)	2/5 (40%)
Cytologic specimens, n= 20/20	No specimens	7/7 (100%)	1/1 (100%)	7/7 (100%)	5/5 (100%)

\*LOX and LOXL2 expression is defined by IHC/ICC intensity score 1+, 2+, 3+


## LOX expression in biopsy and resection specimens is associated with extent of invasion




Needle biopsy immunostaining correlates with tissue immunostaining.  
Spearman's correlation for LOX ICC and LOX IHC,  $r_s = 0.50$ ,  $p = 0.036$ .



# Spearman's rank correlation of LOX expression in biopsy and resection specimens




**LOXL2** expression in resected adenocarcinoma is increased in the progression from AIS to LPA



There is no correlation between LOXL2 ICC and LOXL2 IHC.

# Spearman's rank correlation of **LOXL2** expression in biopsy and resection specimens





# LOX and LOXL2 conclusions

- These data confirm the association between adenocarcinoma invasive subtype and LOX and LOXL2 expression in lung adenocarcinoma.
- **Cellular expression of LOX in pre-resection biopsy specimens is associated with lung adenocarcinoma invasiveness.**
- Prospective validation of tumor biopsy LOX expression patterns in larger sample sets could lead to development of new lung cancer biomarkers. When confirmed, these data suggest a role for LOX immunostaining as a biomarker to predict tumor aggressiveness.





# The tumor microenvironment modulates invasion and metastasis




# Thrombospondin-2 (TSP-2) is a stromal marker of invasion and poor prognosis

- TSP-2 is overexpressed in the stroma of human and murine invasive lung adenocarcinoma.
- Treatment of SKLU-1 cells with exogenous recombinant TSP-2 had no effect on cell proliferation but increased invasion through Matrigel membrane by 2.5-fold.



# RNA Sequencing of invasive and noninvasive lung adenocarcinoma specimens reveals 143 differentially expressed genes

- Supervised clustering of differentially expressed genes for 12 LPA and 21 AIS lung adenocarcinoma specimens.
- Class comparison between invasive (LPA) and noninvasive (AIS) genes was restricted to a significance threshold  $p < 0.01$  and those genes with  $>1.5$ -fold difference in expression.



# Clinical implications

- Biomarkers of invasion in lung adenocarcinoma, such as LOX and LOXL2, MDM2 and CDK4, and TSP-2 may be important mediators of tumor invasion and metastasis.
- High-throughput approaches such as RNA Sequencing will bring forth new targets for prospective validation in larger sample sets.
- **Early prediction of tumor invasion and aggressiveness can stratify risk and guide clinical decision-making regarding optimal therapy for small, early-stage lung cancers.**




# Early Stage Lung Cancer: FNA as a diagnostic tool


# What is an acceptable rate of non-malignant diagnoses in lung cancer resection surgery?

- Principle:
  - Minimize risks in resecting non-malignant lesions.
  - Maximize resection of all lung cancers that require resection.

# What is the role of FNA in the diagnosis of early stage (screen-detected) suspected lung cancer?




# What is the role of FNA in the diagnosis of early stage (screen-detected) suspected lung cancer?



# FNA utility and accuracy

- CT-guided FNA obtains a cytologic aspirate for:
  - H&E staining for cellular morphology
  - Immunohistochemistry for histologic subtyping
  - Cell block preservation for molecular analysis
- A pooled analysis of 24 studies of CT-guided transthoracic needle aspiration revealed:
  - Sensitivity of 0.92 (95% CI, 0.9-0.94)
  - Specificity of 0.97 (95% CI, 0.96-0.98)





# Hypothesis

- **Pre-operative FNA performed in a high-volume lung cancer center will decrease the rate of surgical resection for non-malignant disease.**
- **Objective:** To retrospectively examine the non-malignant resection rate (NMRR) and determine concordance of FNA results and surgical resection pathology.

# Methodology

- Consecutive thoracic operations performed by the Mount Sinai Department of Thoracic Surgery during the 6-month period between February 1, 2014 and August 1, 2014 for known or suspected first primary lung cancer presenting with a lung nodule or mass.
- Not included:
  - Patients with metastatic disease
  - Patients with prior lung cancer
  - Patients who received neoadjuvant chemotherapy prior to surgical resection
- Data extracted from EMR:
  - Patient demographics
  - Smoking history
  - Nodule characteristics
  - Thoracic operation data

# Characteristics of entire cohort

Patient demographics (n=119)		Nodule and operative characteristics (n=127)	
Age, mean $\pm$ SD, y	66.1 $\pm$ 11.2	Nodule size, mean $\pm$ SD, mm	20.9 $\pm$ 11.7
Female, n	81 (64%)	PET scan performed, n	104 (82%)
BMI, mean $\pm$ SD	26.6 $\pm$ 5	PET SUVmax <sup>#</sup> , mean $\pm$ SD	4.3 $\pm$ 3.4
Smoking history		Thoracic operation	
Never smoker, n	37 (29%)	VATS, n	94 (74%)
Current smoker, n	20 (16%)	Thoracotomy, n	33 (26%)
Former smoker, n	70 (55%)	Extent of resection	
Years smoked*, mean $\pm$ SD, y	34 $\pm$ 16.3	Sublobar, n	74 (58%)
COPD or emphysema, n	54 (43%)	Lobectomy, n	53 (42%)
Personal history of cancer, n	39 (31%)		

\*Smoking history available for 120 of 127 current or formerly smoking subjects, with range 3-70 years

<sup>#</sup>SUVmax unavailable for 11 of 105 subjects who underwent PET

# Characteristics of entire cohort


Cytology and pathology results	N (%)
<b>Pre-operative core biopsy</b>	9 (7%)
<b>FNA or core biopsy categorization (n=78, 61%)</b>	
No pre-operative FNA performed	49 (39%)
Malignant	62 (49%)
Suspicious	8 (6%)
Atypical	3 (2%)
Nondiagnostic	2 (1%)
Benign	3 (2%)
<b>Resection pathology</b>	
Primary lung neoplasm	107 (84%)
Non-malignant disease	20 (16%)

\*PET avidity defined as SUVmax >2

# Preliminary results

- 127 surgical resections from 119 patients among 10 cardiothoracic surgeons
- Overall non-malignant resection rate  
(NMRR) = 20/127 **(15.7%)**
  - Among 10 surgeons, the non-malignant resection rate varied from 6.5% to 36%.

# NMRR is decreased in patients with a pre-operative diagnostic FNA






		Resection pathology				
		Malignant (107)	Non-malignant (20)		Malignant (107)	Non-malignant (20)
Pre-operative diagnostic testing	FNA/ Core Positive* (70)	69	1	PET+#	41	0
				PET-	23	1
				No PET	5	0
	FNA Atypical (3)	1	2	PET+	0	1
				PET-	0	1
				No PET	1	0
	FNA/ Core Benign (3)	0	3	PET+	0	3
				PET-	0	0
	FNA/ Core Nondiagnostic (2)	0	2	PET+	0	0
				PET-	0	1
				No PET	0	1
	FNA Not done (49)	37	12	PET+	20	4
				PET-	8	1
				No PET	9	7

\*FNA positive includes Malignant and Suspicious categorizations.

#PET+ defined by SUVmax >2; PET- by SUVmax ≤2.

# A positive FNA result more accurately predicts resection pathology compared with PET



# Characteristics of patients with non-malignant pathology on resection

Patient demographics (n=20)	
Age, mean $\pm$ SD, y	58.2 $\pm$ 11.6
Female, n	10 (50%)
BMI, mean $\pm$ SD	27.8 $\pm$ 5.6
Smoking history	
Never smoker, n	13 (65%)
Current smoker, n	1 (5%)
Former smoker, n	6 (30%)
Years smoked*, mean $\pm$ SD, y	21.5 $\pm$ 7.4
COPD or Emphysema, n	5 (25%)
Personal history of cancer, n	7 (35%)

Nodule and operative characteristics (n=20)	
Nodule size, mean $\pm$ SD, mm	15.7 $\pm$ 8
PET scan performed, n	12 (60%)
PET SUVmax <sup>#</sup> , mean $\pm$ SD	3.1 $\pm$ 1.5
Thoracic operation	
VATS, n	17 (85%)
Thoracotomy, n	3 (15%)
Extent of resection	
Wedge resection, n	18 (90%)
Lobectomy, n	2 (10%)

\*Smoking history available for 4 of 7 current or formerly smoking subjects, with range 5-43 years

<sup>#</sup>SUVmax available for 11 of 12 subjects who underwent PET, with range 1.4-6.

Cytology and pathology results, n	N (%)
<b>Pre-operative core biopsy (nondx or benign)</b>	2 (10%)
<b>FNA categorization</b>	
No pre-operative FNA performed	12 (60%)
Malignant	1 (5%)
Suspicious	0 (0%)
Atypical	2 (10%)
Nondiagnostic	1 (5%)
Benign	2 (10%)
<b>Resection pathology</b>	
Granulomatous disease	12 (60%)
Other	6 (25%)
Organizing pneumonia	2 (10%)
Intra-parenchymal lymph node	1 (5%)
Interstitial/ peribronchial inflammation	1 (5%)
Lymphoplasmacytic infiltrates	1 (5%)
Apical cap	1 (5%)
Benign tumors (hamartoma, inflammatory myofibroblastic tumor)	2 (10%)

\*PET avidity defined as SUVmax >2; PET status unknown for 3 patients.

# FNA Conclusions

- Practice patterns vary widely among cardiothoracic surgeons within a single lung cancer center.
- Non-malignant resection rate is lower in patients who have a pre-operative FNA, compared with those who do not.
- FNA more accurately predicts resection pathology compared with PET among patients who undergo resection for a lung neoplasm.
  - FNA can provide a definitive diagnosis and allows for further molecular studies to be performed on biopsy specimens.



# Future directions

# Additional tumor biology questions

- What are additional pathways important in acquisition of tumor invasiveness and metastasis, and can targeted therapies effectively halt tumor growth and invasion?
- Targets for immune activation and checkpoint inhibition (anti-PD1 and anti-PDL1 antibodies).
- These and other biomarkers can be investigated in neoadjuvant window of opportunity clinical trials of targeted therapeutics.

# Additional clinical questions

- How should screen-detected non-solid lung nodules be managed?
  - How quickly do they grow? Can they be observed?
  - Should sub-solid nodules be resected once a solid component develops?
  - Do biomarkers of invasiveness predict outcome and guide clinical decision making?
- What is the role of limited surgical resection?
  - Do wedge resection and segmentectomy have similar outcomes when compared with lobectomy?
  - Which nodules (size, location, density) are most amenable to sub-lobar resection?

# Summary points

- Pathways for lung cancer metastasis and invasion provide potential targets for therapy and biomarkers by which to guide prognostication and clinical decision-making.
- Clinical workup of nodules suspicious for lung cancer requires further investigation to determine the most accurate diagnostic modalities based upon a priori risk.
- Lung cancer screening for high-risk current and former smokers will further highlight these controversies through a sharp increase in the number of early stage lung cancers. Tools that allow us to distinguish indolent from aggressive tumors will maximize benefit and reduce harms from lung cancer screening.

# Acknowledgements



Icahn  
School of  
Medicine at  
Mount  
Sinai

- **Powell Lab**
  - **Charles A. Powell, MD**
  - Sachiko Takikawa, MD, PhD
- Department of Pathology
  - Mary Beth Beasley, MD
  - Maoxin Wu, MD, PhD
  - Yayoi Kinoshita, MD
- Mount Sinai Biorepository/  
Histology SRF
  - Michael Donovan, MD, PhD
  - Marlon Suarez
- Department of Radiology
  - Claudia I. Henschke, MD, PhD
  - David F. Yankelevitz, MD
- Department of Thoracic Surgery
  - Raja Flores, MD
- Institute of Genomics and  
Multiscale Biology
  - Jun Zhu, PhD
  - Seungyeul Yoo, PhD